BioAge Labs, Inc.
- Stock
- Ticker BIOA
- ISIN US09077V1008
- Nasdaq
Performance, volatility and drawdowns of BioAge Labs, Inc. since 09/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $5,654. Global equities (VT): $10,273.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −88.2% in 04/2025, measured from the peak in 10/2024. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0.0 | 1.5 | 2.4 | 2.1 | 3.1 | 2.8 | 2.5 | 0.3 |
| Operating income | -25 | -16 | -25 | -23 | -28 | -25 | -29 | -37 |
| EBITDA | -25 | – | – | -23 | -28 | – | – | -37 |
| Net income | -21 | -13 | -22 | -20 | -26 | -22 | -26 | -34 |
| Earnings per share | 15.13 | -0.36 | -0.60 | -0.56 | -0.72 | -0.52 | -0.58 | -0.73 |
| Balance sheet | ||||||||
| Total assets | 358 | 344 | 322 | 305 | 295 | 398 | 397 | 368 |
| Liabilities | 35 | 31 | 27 | 28 | 23 | 19 | 22 | 21 |
| Equity | 323 | 313 | 295 | 277 | 272 | 379 | 375 | 346 |
| Cash | 354 | 257 | 220 | 216 | 189 | 242 | 74 | 53 |
| Long-term debt | 2.5 | 1.1 | 0.0 | 0.0 | 0.0 | – | – | – |
| Cash flow | ||||||||
| Operating cash flow | -5.1 | -17 | -20 | -16 | -28 | -24 | -19 | -31 |
| Capital expenditure | 0.0 | -0.4 | -0.2 | 0.0 | -0.1 | 0.0 | -0.3 | 0.0 |
| Free cash flow | -5.2 | -18 | -20 | -16 | -28 | -24 | -20 | -31 |
Value it:DCF calculatorMultiples calculator
Annual returns
* partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 5 Nov 2026 | −$0.73 |
| 5 Aug 2026 | −$0.58 |
| 8 May 2026 | −$0.52 |
| 24 Mar 2026 | −$0.72 |
| 6 Nov 2025 | −$0.56 |
| 6 Aug 2025 | −$0.60 |
| 6 May 2025 | −$0.36 |
| 20 Mar 2025 | $15.13 |
| 7 Nov 2024 | −$8.74 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €178m
- Market cap in trading currency
- $197m
- Enterprise value
- −$86.9m
- P/E
- –
- P/S
- 22.88
- P/B
- 0.57
- EV/Sales
- -10.11
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -52.4%
Results (last four quarters)
- Revenue
- $8.60m
- Gross profit
- –
- EBITDA
- –
- Net income
- −$108m
- Earnings per share
- −$2.55
- Revenue per share
- $0.19
- Revenue growth
- −85.5%
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- -1,401.8%
- Net margin
- -1,253.6%
- Return on equity
- -34.6%
- Return on assets
- -29.3%
Balance sheet and cash flow
- Cash
- $284m
- Cash per share
- $6.17
- Financial debt
- $0
- Debt/equity %
- 0
- Current ratio
- 15.51
- Book value per share
- $7.54
- Operating cash flow
- −$103m
- Free cash flow
- −$103m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 46.0m
- Volume
- 630,035
- Avg. volume 3 months
- 734,744
- Relative volume
- 0.8
Price and technicals
- Price
- $4.28
- 1 day
- −9.1%
- 52-week high
- $25.10
- 52-week low
- $4.28
- Distance to 52-week high
- −82.9%
- Distance to 52-week low
- 0.0%
- Distance to 50-day line
- −30.7%
- Distance to 200-day line
- −71.0%
- RSI (14)
- 27
- Volatility 1M
- 80.2%
Performance
- 1 week
- −22.9%
- 1 month
- −22.6%
- 3 months
- −54.4%
- 6 months
- −74.2%
- YTD
- −67.6%
- 1 year
- −48.1%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has BIOA performed since 09/2024?
$10,000 grew to $2,338 by 20 Nov 2026, which is −49.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is BIOA?
Volatility was 98.0% per year, measured on monthly returns. The largest decline from a peak was −88.2%, with the low in 04/2025.
How does BIOA compare with a broad equity ETF?
Over the same period Global equities (VT) returned +10.0% per year at 13.2% volatility, BIOA returned −49.2% at 98.0%. The correlation of monthly returns was 0.34; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.